Physician profile
Scott C Layne
NPI 1922106749
$7,223.67
in general payments reported to CMS, 2019-2025
42 companies · $1,026 in 2025
The $1,026 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $870 · 2020: $927 · 2021: $1,307 · 2022: $1,324 · 2023: $1,028 · 2024: $742 · 2025: $1,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,795.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,354.90 | 2019-2025 | |
| Novo Nordisk INC | $1,022.98 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $921.56 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $423.46 | 2019-2025 | Verquvo, Belsomra, Gardasil 9 |
| Glaxosmithkline, LLC. | $405.79 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $305.92 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $292.55 | 2019-2025 | Ofev, Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $260.81 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $191.55 | 2019-2022 | |
| Abbott Laboratories | $188.83 | 2021-2023 | Freestyle Libre 2 |
| Amgen INC. | $180.62 | 2019-2023 | Prolia, Evenity |
| Lilly USA, LLC | $180.51 | 2020-2025 | Mounjaro, Zepbound, Kisunla |
| Allergan, INC. | $174.65 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $168.64 | 2021-2022 | |
| Esperion Therapeutics, INC. | $121.23 | 2020-2025 | Nexletol |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Layne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.